WO2014090692A1 - Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer - Google Patents

Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer Download PDF

Info

Publication number
WO2014090692A1
WO2014090692A1 PCT/EP2013/075751 EP2013075751W WO2014090692A1 WO 2014090692 A1 WO2014090692 A1 WO 2014090692A1 EP 2013075751 W EP2013075751 W EP 2013075751W WO 2014090692 A1 WO2014090692 A1 WO 2014090692A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
phenyl
ylamino
mmol
indazol
Prior art date
Application number
PCT/EP2013/075751
Other languages
English (en)
Inventor
Zhanling CHENG
Xingchun Han
Min Jiang
Jianhua Wang
Min Wang
Song Yang
Chengang ZHOU
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Priority to MX2015007097A priority Critical patent/MX2015007097A/es
Priority to EP13799602.1A priority patent/EP2928893A1/fr
Priority to BR112015008037A priority patent/BR112015008037A2/pt
Priority to JP2015546021A priority patent/JP2016501251A/ja
Priority to KR1020157017861A priority patent/KR20150092279A/ko
Priority to CA2885392A priority patent/CA2885392A1/fr
Priority to RU2015124917A priority patent/RU2015124917A/ru
Priority to CN201380064513.2A priority patent/CN104837842A/zh
Publication of WO2014090692A1 publication Critical patent/WO2014090692A1/fr
Priority to US14/735,348 priority patent/US20150266878A1/en
Priority to HK16101393.3A priority patent/HK1213544A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Definitions

  • the present invention relates to organic compounds useful for therapy in a mammal, and in particular to inhibit cell proliferation and induce cell cycle arrest and apoptosis that overexpress CDK8 or Cyclin C useful for treating cancer.
  • CDK cyclin-dependent kinase
  • Dysregulation of CDKs has been linked to pathological events and both proliferative and non-pro liferative disease, including cancers, Alzhemers disease (AD), parkinson's disease, Stroke/ischemia, pain, traumatic brain injury, kidney disease, inflammation pathologies, type 2 diabetes, viral infection (HSV, HCMV, HPV, HIV).
  • CDK8 is a CyclinC-dependent CDK family kinase and functions as a transcriptional regulator.
  • RNAPII R A polymerase II
  • CCD C-terminal domain
  • GTFs general transcription factors
  • CDK8 has also been described as a transcriptional coactivator in oncongenic signaling pathways, including the ⁇ -catenin pathway, the serum response network, the Tumor Growth Factor TGFP signaling pathway, the p53 pathway, as well as in thyroid hormone-dependent transcription. Co localization of CDK8 and Cyclin C was also reported in neurodegenerative disease such as AD. CDK8 was found to be frequently
  • Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I for the treatment of cancer.
  • Ci_ 6 alkyl alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1-butyl, 2-butyl, tert-butyl and the like.
  • Particular "Ci_ 6 alkyl” groups are methyl, ethyl, isopropyl and tert-butyl.
  • Ci_6alkoxy alone or in combination signifies a group Ci_6alkyl-0-, wherein the "Ci_6alkyl” is as defined above; for example methoxy, ethoxy, propoxy, z ' so-propoxy, n-butoxy, zso-butoxy, 2-butoxy, tert-butoxy and the like.
  • Particular "Ci_6alkoxy” groups are methoxy and ethoxy and more particularly methoxy.
  • C X H 2X alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms.
  • C y H 2y alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 2 to 6, particularly 2 to 4 carbon atoms.
  • cycloalkyl refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular
  • cycloalkyl groups are cyclopropyl, cyclopentyl and cyclohexyl.
  • amino alone or in combination, refers to primary (-NH 2 ), secondary (-NH-) or
  • halogen means fluorine, chlorine, bromine or iodine. Halogen is particularly fluorine or chlorine.
  • hydroxy alone or in combination refers to the group -OH.
  • carbonyl alone or in combination refers to the group -C(O)-.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as /?-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H., et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Particular are the sodium salts of the compounds of formula I.
  • Racemates can be separated according to known methods into the enantiomers.
  • diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
  • the present invention provides (i) novel compounds having the general formula I:
  • R 2 is aminocarbonyl, Ci_6alkoxy-C y H 2y -amino-C x H 2x -, Ci_6alkoxy-C x H 2x -sulfonylamino- C x H 2x -, Ci_6alkylcarbonylamino-C x H 2x -, Ci_6alkylsulfonylamino-C x H 2x -,
  • cycloalkylcarbonylamino-C x H 2x - cycloalkylsulfonylamino-C x H 2x -, hydroxy-C x H 2x -, hydroxy- C y H2y-amino-C x H 2x -, hydroxy-C x H 2x -carbonylamino-C x H 2x - or phenylcarbonylamino-C x H 2x -;
  • R 3 is phenyl, which is unsubstituted or substituted by halogen
  • R 4 is hydrogen, Ci_ 6 alkyl or halogen
  • R 5 is hydrogen, Ci_ 6 alkyl or halogen
  • R 4 and R 5 together with the carbon atom, to which they are attached, form cycloalkyl;
  • R 6 is hydrogen or halogen;
  • R 7 is hydrogen, Ci_ 6 alkyl, Ci_ 6 alkylsulfanyl, Ci_ 6 alkylsulfonyl, amino or halogen;
  • x is 1-6;
  • y is 2-6;
  • Another embodiment of present invention is (ii) a compound of formula I, wherein R 1 is selected from
  • R 2 is aminocarbonyl, Ci_6alkoxy-C y H 2y -amino-C x H 2x -, Ci_6alkoxy-C x H 2x -sulfonylamino- C x H 2x -, Ci_6alkylcarbonylamino-C x H 2x -, Ci_6alkylsulfonylamino-C x H 2x -,
  • cycloalkylcarbonylamino-C x H 2x - cycloalkylsulfonylamino-C x H 2x -, hydroxy-C x H 2x -, hydroxy- C y H2y-amino-C x H 2x -, hydroxy-C x H 2x -carbonylamino-C x H 2x - or phenylcarbonylamino-C x H 2x -;
  • R 3 is phenyl, which is unsubstituted or once substituted by halogen
  • R 4 is hydrogen, Ci_ 6 alkyl or halogen
  • R 5 is hydrogen, Ci_ 6 alkyl or halogen
  • R 4 and R 5 together with the carbon atom, to which they are attached, form cycloalkyl;
  • R 6 is hydrogen or halogen;
  • R 7 is hydrogen, Ci_ 6 alkyl, Ci_ 6 alkylsulfanyl, Ci_ 6 alkylsulfonyl, amino or halogen;
  • x is 1-6;
  • y is 2-6;
  • R 2 is aminocarbonyl, methoxyethylaminomethyl, methoxyethylsulfonylaminomethyl, methylcarbonylammomethyl, ethylcarbonylammomethyl, isopropylcarbonylammomethyl, methylsulfonylammomethyl, cyclohexylcarbonylammomethyl, cyclopropylsulfonylammomethyl, hydroxymethyl, hydroxyethylaminomethyl, hydroxymethylcarbonylaminomethyl or
  • R 3 is phenyl or chlorophenyl
  • R 4 is hydrogen, methyl or fluoro
  • R 5 is hydrogen, methyl or fluoro
  • R 6 is hydrogen or fluoro
  • R 7 is hydrogen, methyl, ethyl, methylsulfanyl, methylsulfonyl, amino, fluoro or chloro; or pharmaceutically acceptable salt thereof.
  • Another embodiment of present invention is (iv) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • R 2 is aminocarbonyl, Ci_6alkylcarbonylamino-C x H 2X - or hydro xy-C x H 2X -;
  • R 3 is phenyl, which is unsubstituted or once substituted by halogen
  • R 4 is hydrogen, Ci_ 6 alkyl or halogen
  • R 5 is hydrogen, Ci_ 6 alkyl or halogen
  • R 4 and R 5 together with the carbon atom, to which they are attached, form cycloalkyl;
  • R 6 is hydrogen or halogen;
  • x is 1-6.
  • R 2 is aminocarbonyl, methylcarbonylaminomethyl or hydroxymethyl
  • R 3 is phenyl or chlorophenyl
  • R 4 is hydrogen, methyl or fluoro
  • R 5 is hydrogen, methyl or fluoro
  • R 4 and R 5 together with the carbon atom, to which they are attached, form cyclopropyl; R 6 is hydrogen or fluoro.
  • Another embodiment of present invention is (vi) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • R 2 is aminocarbonyl, Ci_6alkoxy-C y H 2y -amino-C x H 2x -, Ci_6alkoxy-C x H 2x - sulfonylamino-C x H 2x -, Ci_6alkylcarbonylamino-C x H 2x -, Ci_6alkylsulfonylamino-C x H 2x -, cycloalkylcarbonylamino-C x H 2x -, cycloalkylsulfonylamino-C x H 2x -, hydroxy-C x H 2x -, hydroxy-C y H2y-amino-C x H 2x -, hydroxy-C x H 2x -carbonylamino-C x H 2x - or
  • R 3 is phenyl
  • R 7 is hydrogen, Ci_ 6 alkyl, Ci_ 6 alkylsulfanyl, Ci_ 6 alkylsulfonyl, amino or halogen; x is 1-6;
  • y is 2-6.
  • R 2 is aminocarbonyl, methoxyethylammomethyl, methoxyethylsulfonylammomethyl, methylcarbonylammomethyl, ethylcarbonylammomethyl, isopropylcarbonylammomethyl, methylsulfonylaminomethyl, cyclohexylcarbonylaminomethyl,
  • R 3 is phenyl
  • R 7 is hydrogen, methyl, ethyl, methylsulfanyl, methylsulfonyl, amino, fluoro or chloro.
  • Another embodiment of present invention is (viii) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • R 2 is aminocarbonyl or hydroxy-C x H 2x -;
  • R 3 is phenyl
  • x is 1-6.
  • Further embodiment of present invention is (ix) a compound of formula I or a pharmaceutically acceptable salt thereof, wherein
  • R is aminocarbonyl or hydroxymethyl
  • R 3 is phenyl
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1 , R 2 and R 3 are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
  • Intermediate III can be synthesized via Mitsunobu reaction between compound II- 1 and isoindole-l ,3-dione. The reaction can be carried out in the presence of DEAD and PPh 3 in THF. Ammonolyze of intermediate III affords compound II-2. Connection between compound II-2 and Ci_6alkylsulfonyl chloride, Ci_6alkyl or Ci_6alkyl acid affords intermediate II-3.
  • X is chloro, bromo or iodo.
  • the compound of formula la can be prepared according to Scheme 2.
  • boronic acid IV can be prepared by the reaction of intermediate II and bis(pinacolato)diboron in the presence of Pd catalyst and followed by hydro lyze reaction. Then coupling between intermediate IV and halide affords compound la.
  • compound la can be prepared by one-pot reaction.
  • Compound II reacts with bis(pinacolato)diboron, and in the presence of Pd catalyst such as tris(dibenzylideneacetone) dipalladium and a ligand such as butyldi-l-adamantylphosphine, then halide R J -X is added and the mixture is stirred at 100 °C for several hours under microwave to afford compound la.
  • Pd catalyst such as tris(dibenzylideneacetone) dipalladium
  • a ligand such as butyldi-l-adamantylphosphine
  • Intermediate V can be synthesized via the introduction of iodine to the 3- position of indazole.
  • Compound VI can be prepared by intermediate V and MeSNa solution in the presence of Cul.
  • One-pot reaction as described in Method 3 in Scheme 2 affords compound lb.
  • Oxidization of the compound lb in the presence of oxone in DMF affords compound Ic.
  • R" is Ci_ 6 alkyl or Ci_ 6 alkoxy-CH 2 -.
  • the compound of formula le can be prepared according to Scheme 4. Reduction of amide Id in the presence of BH 3 in THF at 80 °C overnight affords le.
  • This invention also relates to a process for the preparation of a compound of formula I comprising the reaction of
  • R 1 , R 2 and R 3 are defined above unless otherwise indicated; X is chloro, bromo or iodo; R" is Ci_ 6 alkyl or Ci_6alkoxy-CH 2 -.
  • the catalyst in step (a), can be for example Pd(PPh 3 ) 4 , PdCl 2 (PPh 3 ) 2 , the base can be for example K 3 P0 4 , Na 2 C0 3 , K 2 C0 3 or Cs 2 C0 3 ;
  • the catalyst can be for example Pd(PPh 3 ) 4
  • the base can be for example K 2 C0 3
  • the catalyst can be for example tris(dibenzylideneacetone) dipalladium
  • the ligand can be for example butyldi-l-adamantylphosphine
  • the catalyst can be for example Pd(dppf)Cl 2 .
  • a compound of formula I when manufactured according to the above process is also an object of the invention.
  • the invention also relates to a compound of formula I for use as therapeutically active substance.
  • Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.
  • compounds of formula I may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • physiologically acceptable carriers i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but particularly ranges anywhere from about 3 to about 8.
  • a compound of formula I is formulated in an acetate buffer, at pH 5.
  • the compounds of formula I are sterile.
  • the compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit CDK8 activity. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.
  • the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.1 to 50 mg/kg of patient body weight per day, with the typical initial range of compound used being about 0.3 to about 15 mg/kg/day.
  • oral unit dosage forms such as tablets and capsules, preferably contain from about 5 mg to about 500 mg of the compound of the invention.
  • the compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • the compounds of the present invention may be administered in any convenient
  • compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient.
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical
  • composition thereof or aid in the manufacturing of the pharmaceutical product (i.e.,
  • An example of a suitable oral dosage form is a tablet containing about 5 mg to 500 mg of the compound of the invention compounded with about 90 mg to 30 mg anhydrous lactose, about 5 mg to 40 mg sodium croscarmellose, about 5 mg to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 mg to 10 mg magnesium stearate.
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment.
  • An example of an aerosol formulation can be prepared by dissolving the compound, for example 5mg to 400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired.
  • the solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants
  • An embodiment therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
  • Another embodiment includes a pharmaceutical composition comprising a compound of Formula I for use in the treatment of a hyperproliferative disease. Another embodiment includes a pharmaceutical composition comprising a compound of Formula I for use in the treatment of cancer.
  • the compounds of the invention inhibit the kinase activity of protein. Accordingly, the compounds of the invention are useful for inhibiting cell proliferation and inducing cell cycle arrest and apoptosis in particular cancer cells.
  • Compounds of the invention are useful for inhibiting cell proliferation, inducing cell cycle arrest and apoptosis in cells that overexpress CDK8 or Cyclin C.
  • compounds of the invention are useful for inhibiting cell proliferation, inducing cell cycle arrest and apoptosis in cells in which the apoptotic pathway is disrupted or proliferation pathway is overexpressed/or immortalized, for example by deregulation of CDK8 or Cyclin C.
  • the compounds of inventions are useful as inhibitors of CDK8 or Cyclin C.
  • An embodiment of this invention includes the use of a compound for the treatment of cancer, in particular bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, liver, skin, hematopoetic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small-cell lung, glioma, colorectal and pancreatic cancers.
  • a further embodiment of this invention includes the use of a compound for the treatment of gastric cancer or colorectal cancer.
  • Another embodiment of this invention includes the use of a compound for the preparation of a medicament for the treatment of cancer, in particular bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, liver, skin, hematopoetic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small-cell lung, glioma, colorectal and pancreatic cancers.
  • a further embodiment of this invention includes the use of a compound for the preparation of a medicament for the treatment of gastric cancer or colorectal cancer.
  • Another embodiment of this invention relates to a compound of formula I for the treatment of cancer, in particular bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, liver, skin, hematopoetic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small-cell lung, glioma, colorectal and pancreatic cancers.
  • a further embodiment of this invention relates to a compound of formula I for the treatment of gastric cancer or colorectal cancer.
  • Another embodiment includes a method of treating or preventing cancer in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
  • a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof include bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, liver, skin, hematopoetic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, small-cell lung, glioma, colorectal and pancreatic cancers.
  • the invention relates to a method of treating or preventing gastric cancer or colorectal cancer in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
  • Another embodiment includes a method of treating or preventing neurodegenerative disease in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug or
  • Particular neurodegenerative disease for treatment includes Alzhemers disease, parkinson's disease, Huntington's dsease and Amyotrophic lateral sclerosis (ALS).
  • ALS Amyotrophic lateral sclerosis
  • the compounds of the invention can be used in combination with small molecule inhibitors such as tyrosine kinase inhibitors, Serine/Threonine kinase inhibitors, lipid kinase inhibitors, protein-protein inhibitors, etc., cytotoxic agents, radiotherapy, antibodies and cancer vaccines for the treatment of cancer.
  • small molecule inhibitors such as tyrosine kinase inhibitors, Serine/Threonine kinase inhibitors, lipid kinase inhibitors, protein-protein inhibitors, etc.
  • cytotoxic agents such as tyrosine kinase inhibitors, Serine/Threonine kinase inhibitors, lipid kinase inhibitors, protein-protein inhibitors, etc.
  • BSA bovine serum albumin
  • DIPEA N,N-diisopropylethylamine
  • EGTA ethylene glycol tetraacetic acid
  • HATU 2-(7-aza- IH-benzotriazole- 1 -yl)- 1 , 1 ,3,3-tetramethyluronium hexafluoropho sphate
  • HCMV human cytomegalovirus
  • HIV human immunodeficiency
  • HSV herpes simplex virus
  • HPV human papillomavirus
  • nM nano moles per liter
  • Pd(PPli 3 )4 tetrakis(triphenylphosphine)palladium
  • Pd(PPh 3 ) 2 Cl 2 bis(triphenylphosphine)palladium(II) chloride
  • LC/MS spectra were obtained using a MicroMass Plateform LC (WatersTM alliance 2795- ZQ2000). Standard LC/MS conditions were as follows (running time 6 minutes): Acidic condition: A: 0.1% formic acid in H 2 0; B: 0.1% formic acid in acetonitrile;
  • Mass spectra generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (M+H) + .
  • the microwave assisted reactions were carried out in a Biotage Initiator Sixty.
  • Step 3 Preparation of 5-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]-l,3- dihydro-indol-2-one
  • Example 2 Preparation of 5-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]- 3,3-dimethyl- 1 , 3-dihydro-indol-2-one Under an Ar atmosphere, a mixture of (i?)-5-(2-hydroxy-l-phenylethyl)-amino)-pyridin-3- yl)-boronic acid (100 mg, 0.4 mmol), 5-bromo-3,3-dimethyl-l ,3-dihydro-indol-2-one (93 mg, 0.4 mmol), tetrakis(triphenylphosphine)palladium (25 mg) and potassium carbonate (1 10 mg, 0.8 mmol) in DME/H 2 0 (5 : 1 , 5 mL) was heated at 90 °C under microwave for 40 mins.
  • DME/H 2 0 5 : 1 , 5 mL
  • Step 2 Preparation of 5- ⁇ 5-[(R)-l-(2-chloro-phenyl)-2-hydroxy-ethylamino]-pyridin- 3-yl ⁇ - 1 ,3-dihydro-indol-2-one
  • Step 1 Preparation of spiro(cyclopropane-l,3-indolin)-2-one-5-boronic acid pinacol ester
  • Step 2 Preparation of (R)-5'-(5-((2-hydroxy-l-phenylethyl)amino)pyridin-3-yl)- spiro [cyclopropane-1,3 '-indolin] -2'-one
  • Step 1 Preparation of 5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-l,3-dihydro- pyrrolo [2,3-b] pyridin-2-one
  • Step 2 Preparation of 5-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]-l,3- dihydro-pyrrolo [2,3-b] pyridin-2-one
  • Step 1 Preparation of 3,3-difluoro-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- 1 ,3-dihydro-indol-2-one
  • Step 2 Preparation of 3,3-difluoro-5-[5-((R)-2-hydroxy-l-phenyl-ethylamino)- pyridin-3-yl] - 1 ,3-dihydro-indol-2-one
  • Step 2 Preparation of 5-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]-l,3- dihydro-pyrrolo [3,2-b] pyridin-2-one Under an Ar atmosphere, a mixture of crude (2-oxo-2,3-dihydro-lH-pyrrolo[3,2- b]pyridine-5-yl)boronic acid (273 mg), (i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethanol (535 mg, 1.831 mmol), bis(triphenylphosphine)palladium(II) chloride (198 mg, 0.28 mmol) and potassium carbonate (583 mg, 4.21 mmol) in DMF/H 2 0 (5 : 1, 10 mL) was exposed to microwave irradiation at 100 °C for 1 hour.
  • Example 12 Preparation of 6-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]- 3H-benzooxazol-2-one 6-Bromo-3H-benzooxazol-2-one (428 mg, 2.0 mmol), bis(pinacolato)diboron (508 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium (55 mg, 0.06 mmol), butyldi-1- adamantylphosphine (65 mg, 0.18 mmol), potassium acetate (588 mg, 6.0 mmol) were added into a 10 mL microwave vial containing a magnetic stirrer bar, followed by isopropyl acetate (1.5 mL).
  • Step 1 Preparation of 6-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-3H- benzothiazol-2-one
  • Step 2 Preparation of 6-[5-((R)-2-hydroxy-l-phenyl-ethylamino)-pyridin-3-yl]-3H- benzothiazol-2-one Under an Ar atmosphere, a mixture of (i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl- ethanol (300 mg, 1.027 mmol), 6-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-3H- benzothiazol-2-one (284 mg, 1.027 mmol), tetrakis(triphenylphosphine)palladium (59 mg, 0.051 mmol) and potassium carbonate (425 mg, 3.08 mmol) in DME/H 2 0 (5: 1, 10 mL) was exposed to microwave irradiation at 100 °C for 5 hours, then concentrated in vacuo.
  • Step 1 Preparation of 3-fluoro-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- indazole
  • Step 2 Preparation of (R)-2-[5-(3-fluoro-lH-indazol-5-yl-pyridin-3-ylamino]-2- phenyl-ethanol
  • Step 1 Preparation of 3-methyl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- indazole
  • Step 2 Preparation of (R)-2-[5-(3-methyl-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethanol
  • Step 3 Preparation of (R)-2-[5-(3-methylsulfanyl-lH-indazol-5-yl)-pyridin-3- ylamino] -2-phenyl-ethanol
  • Step 1 Preparation of 3-chloro-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- indazole
  • Step 2 Preparation of (R)-2-[5-(3-chloro-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethanol
  • Step 3 Preparation of (5-((2-amino-2-oxo-l-phenylethyl)amino)pyridin-3-yl) boronic acid
  • Step 4 Preparation of 2-[5-(2-oxo-2,3-dihydro-lH-indol-5-yl)-pyridin-3-ylamino]-2- phenyl-acetamide
  • Step 1 Preparation of 2-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- isoindole-l,3-dione
  • Step 2 Preparation of (R -TV ⁇ -iS-bromo-pyridin-S-ylJ-l-phenyl-ethane-ljl-diamine
  • Step 3 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- acetamide
  • Step 4 Preparation of V- ⁇ (R)-2-[5-(2-oxo-2,3-dihydro-lH-indol-5-yl)-pyridin-3- ylamino]-2-phenyl-ethyl ⁇ -acetamide
  • N-[(i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-acetamide (67 mg, 0.2 mmol), 5- (4,4,5,5-tetramethyl-[l ,3,2]dioxaborolan-2-yl)-l ,3-dihydro-indol-2-one (67 mg, 0.26 mmol), tetrakis(triphenylphosphine) palladium (1 1 mg, 0.01 mmol) and potassium carbonate (81 mg, 0.6 mmol) were added into a 10 mL microwave vial containing a magnetic stirrer bar, followed by 1 ,4-dioxane (1 mL) and H 2 0 (0.2 mL).
  • the vessel was sealed with a cap under an argon atmosphere, and then the resulting mixture was heated to 100 °C for 2 hours under microwave.
  • the mixture was cooled to room temperature and diluted with water (5 mL), extracted with ethyl acetate (10 mL x 3), the combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, concentrated in vacuo to give crude title compound.
  • the vessel was sealed with a cap under an argon atmosphere, and then the resulting mixture was heated to 83 °C for 1 hour. After the reaction was completed as monitored by TLC and LC-MS, 2-(5-bromo-pyridin-3-ylamino)-2-phenyl-acetamide (73 mg, 0.24 mmol), potassium carbonate (99 mg, 0.72 mmol), DME (0.75 mL) and H 2 0 (0.3 mL) were added into the above mixture successively. The vessel was sealed with a cap under an argon atmosphere, and then the reaction mixture was heated to 90 °C for 40 minutes under microwave.
  • 6-Bromo-3,4-dihydro-lH-quinolin-2-one 45 mg, 0.2 mmol
  • bis(pinacolato)diboron 51 mg, 0.204 mmol
  • tris(dibenzylideneacetone)dipalladium 5.5 mg, 0.006 mmol
  • butyldi-1- adamantylphosphine 6.5 mg, 0.018 mmol
  • potassium acetate 59 mg, 0.6 mmol
  • the vessel was sealed with a cap under an argon atmosphere, and then the resulting mixture was heated to 83 °C for 1 hour. After the reaction was completed as monitored by TLC and LC-MS, 2-(5-bromo-pyridin-3-ylamino)-2-phenyl-acetamide (61 mg, 0.2 mmol), potassium carbonate (81 mg, 0.6 mmol), isopropyl acetate (0.55 mL) and H 2 0 (0.2 mL) were added into the above mixture successively. The vessel was sealed with a cap under an argon atmosphere, then the reaction mixture was heated to 90 °C for 40 mins under microwave.
  • Example 34 Preparation of 2-[5-(7-fluoro-2-oxo-l,2,3,4-tetrahydro-quinolin-6-yl)- pyridin-3-ylamino]-2-phenyl-acetamide 6-Bromo-7-fluoro-3,4-dihydro-lH-quinolin-2-one (73 mg, 0.3 mmol),
  • Step 2 Preparation of 2- [5-(lH-indazol-5-yl)-pyridin-3-ylamino] -2-phenyl-acetamide
  • 2-(5-bromo-pyridin-3-ylamino)-2-phenyl-acetamide (306 mg, 1.0 mmol) in DME/H 2 0 (5 : 1, 12 mL) was added Pd(PPh 3 ) 4 (230 mg, 0.2 mmol), K 2 C0 3 (276 mg, 2.0 mmol) and indazole-5-boronic acid pinacol ester (244 mg, 1.0 mmol).
  • Pd(PPh 3 ) 4 230 mg, 0.2 mmol
  • K 2 C0 3 (276 mg, 2.0 mmol
  • indazole-5-boronic acid pinacol ester 244 mg, 1.0 mmol
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- methanesulfonamide
  • Step 2 Preparation of V- ⁇ (R)-2-[5-(lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl- ethyl ⁇ -methanesulfonamide
  • Step 2 Preparation of 3-fluoro-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- indazole
  • Step 3 Preparation of 2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl- acetamide
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- propionamide
  • Step 2 Preparation of N- ⁇ (R)-2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -propionamide
  • N-[(i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-propionamide 210 mg, crude
  • potassium carbonate 99 mg, 0.72 mmol
  • 1,4-dioxane 0.75 mL
  • H 2 0 0.3 mL
  • the vessel was sealed with a cap under an argon atmosphere, and then the reaction mixture was heated to 100 °C for 2 hours under microwave.
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- isobutyramide
  • Step 2 Preparation of V- ⁇ (R)-2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -isobutyramide
  • N-[(i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- isobutyramide (220 mg, crude), potassium carbonate (99 mg, 0.72 mmol), 1,4-dioxane (0.75 mL) and H 2 0 (0.3 mL) were added into the reaction mixture successively.
  • the vessel was sealed with a cap under an argon atmosphere, and then the reaction mixture was heated to 100 °C for 2 hours under microwave.
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-2- methoxy-acetamide
  • Step 2 Preparation of V- ⁇ (R)-2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -2-methoxy-acetamide
  • Step 3 Preparation of (R)- V i -[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-yl]- V 2 -(2- methoxy-ethyl)- 1-phenyl-ethane- 1 ,2-diamine
  • N- ⁇ (i?)-2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl- ethyl ⁇ -2-methoxy-acetamide 80 mg, 0.19 mmol
  • THF 5 mL
  • BH 3 solution 3.8 mL, 3.8 mmol
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-2- hydroxy-acetamide
  • Step 2 Preparation of V- ⁇ (R)-2-[5-(3-fluoro-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -2-hydroxy-acetamide
  • N- ⁇ (i?)-2-[5-(3-fluoro- lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -2-hydroxy- acetamide 150 mg, 0.37 mmol was dissolved in THF (5 mL) and a solution of BH 3 (7.5 mL, 1.0 M in THF) was added. The mixture was heated to 80 °C and stirred overnight. After cooling down to room temperature, the reaction mixture was quenched with 1M HC1, and then concentrated under reduced pressure to remove half of the solvent. Then saturated NaHC0 3 was added to the residue to neutralization. The mixture was extracted with ethyl acetate (30 mL x 3).
  • Step 2 Preparation of 2-[2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-isoindole- 1,3-dione
  • Step 3 Preparation of ⁇ -(S-bromo-pyridin-S-ylJ-l-phenyl-ethane-l ⁇ -diamine
  • Step 4 Preparation of V-[2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- methanesulfonamide
  • Step 5 Preparation of V- ⁇ 2-[5-(3-methyl-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -methanesulfonamide
  • Example 51 Preparation of cyclopropanesulfonic acid ⁇ (R)-2-[5-(3-methyl-lH- indazol-5-yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -amide
  • Step 1 Preparation of cyclopropanesulfonic acid [(R)-2-(5-bromo-pyridin-3- ylamino)-2-phenyl-ethyl] -amide
  • Step 2 Preparation of cyclopropanesulfonic acid ⁇ (R)-2-[5-(3-methyl-lH-indazol-5- yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -amide 5-Bromo-3-methyl-lH-indazole (63 mg, 0.3 mmol), bis(pinacolato)diboron (78 mg, 0.306 mmol), tris(dibenzylideneacetone)dipalladium (8.2 mg, 0.009 mmol), butyldi-1- adamantylphosphine (9.7 mg, 0.027 mmol), potassium acetate (88 mg, 0.9 mmol) were added into a 10 mL microwave vial containing a magnetic stirrer bar, followed by DME (1 mL).
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- methanesulfonamide
  • Step 1 Preparation of 2-methoxy-ethanesulfonic acid [(R)-2-(5-bromo-pyridin-3- ylamino)-2-phenyl-ethyl] -amide
  • Step 2 Preparation of 2-methoxy-ethanesulfonic acid ⁇ (R)-2-[5-(3-methyl-lH-indazol- 5-yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -amide
  • N-[(i?)-2-(5-Bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-2-hydroxy-acetamide (350 mg, 1.0 mmol), 3-methyl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-indazole (390 mg, 1.5 mmol) and K 2 CO 3 (550 mg, 4.0 mmol) in dioxane /H 2 0 (5 mL / 1 mL) was degassed and charged with N 2 . Then Pd(PPh 3 ) 4 (58 mg, 0.05 mmol) was added and the mixture was heated to 150 °C in microwave reactor for 2 hours.
  • reaction mixture was purified by flash column to give 2-hydroxy-N- ⁇ (i?)-2-[5-(3-methyl- lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ - acetamide (120 mg).
  • Example 55 Preparation of (R)- V 2 -(2-methoxy-ethyl)- V i -[5-(3-methyl-lH-indazol-5- yl)-pyridin-3-yl] - 1-phenyl-ethane- 1 ,2-diamine
  • Step 1 Preparation of 2-methoxy-N- ⁇ (R)-2-[5-(3-methyl-lH-indazol-5-yl)-pyridin-3- ylamino]-2-phenyl-ethyl ⁇ -acetamide
  • N-[(i?)-2-(5-Bromo-pyridin-3-ylamino)-2-phenyl-ethyl]-2-methoxy-acetamide 230 mg, 0.63 mmol
  • 3-methyl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-indazole 196 mg, 0.76 mmol
  • K 2 CO 3 210 mg, 1.52 mmol
  • Step 2 Preparation of (R)- V 2 -(2-methoxy-ethyl)- V i -[5-(3-methyl-lH-indazol-5-yl)- pyridin-3-yl]-l-phenyl-ethane-l,2-diamine
  • N- ⁇ (i?)-2-[5-(3-fluoro- lH-indazol-5-yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -2-hydroxy- acetamide 100 mg, 0.25 mmol was dissolved in THF (5 mL) and a solution of BH 3 (5.0 mL, 1.0 M in THF) was added. The mixture was heated to 80 °C and stirred overnight. After cooling down to room temperature, the reaction mixture was quenched with 1M HC1. The reaction mixture was concentrated under reduced pressure to remove half of the solvent.
  • Step 1 Preparation of cyclohexanecarboxylic acid [(R)-2-(5-bromo-pyridin-3- ylamino)-2-phenyl-ethyl] -amide
  • Step 2 Preparation of cyclohexanecarboxylic acid ⁇ (R)-2-[5-(3-methyl-lH-indazol-5- yl)-pyridin-3-ylamino]-2-phenyl-ethyl ⁇ -amide
  • Step 1 Preparation of V-[(R)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- benzamide
  • Step 2 Preparation of V- ⁇ (R)-2-[5-(3-methyl-lH-indazol-5-yl)-pyridin-3-ylamino]-2- phenyl-ethyl ⁇ -benzamide
  • N-[(i?)-2-(5-bromo-pyridin-3-ylamino)-2-phenyl-ethyl]- benzamide (135 mg, crude), potassium carbonate (124 mg, 0.9 mmol), 1 ,4-dioxane (2 mL) and H 2 0 (0.6 mL) were added into the reaction mixture successively.
  • the vessel was sealed with a cap under an argon atmosphere.
  • the reaction mixture was heated to 100 °C for 2 hours under microwave.
  • the mixture was cooled to room temperature and diluted with water (5 mL), extracted with ethyl acetate (10 mL x 3).
  • Example 61 CDK8/Cyclin C LANCE TR-FRET kinase assay: The biological activity of the compounds of the invention can be determined using the assay described below.
  • CDK8/Cyclin C protein was obtained from Invitrogen, cat# PV4402.
  • UZJg/zt-Glycogen Synthase (Ulight-GS) peptide with sequence PASVPPSPSLSRHSSPHQ(pS)ED, and Europium- anti-phospho Glycogen Synthase (Ser641) [Eu-anti-P-GS (Ser641)] were obtained from Perkin Elmer, cat# TRF0131-M and cat# TRF0220.
  • Adenosine-5 '-triphosphate (ATP) was obtained from Invitrogen, cat# PV3227.
  • Example 62 In vitro cell proliferation assay:
  • the compounds of the present invention were tested for their capacity to inhibit a CDK8 activity and activation as described herein.
  • the Examples were tested in the above assay and found to have IC 50 of about 0.0001 ⁇ to about 30 ⁇ .
  • Particular compounds of formula I were found to have IC 50 of about 0.0001 ⁇ to about 1 ⁇ .
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Abstract

L'invention concerne de nouveaux composés de formule générale (I), dans laquelle R1, R2 et R3 ont la signification indiquée dans la description, des compositions comprenant les composés et des procédés d'utilisation desdits composés.
PCT/EP2013/075751 2012-12-10 2013-12-06 Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer WO2014090692A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2015007097A MX2015007097A (es) 2012-12-10 2013-12-06 Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
EP13799602.1A EP2928893A1 (fr) 2012-12-10 2013-12-06 Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer
BR112015008037A BR112015008037A2 (pt) 2012-12-10 2013-12-06 compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
JP2015546021A JP2016501251A (ja) 2012-12-10 2013-12-06 がんの治療のための新規二環フェニル−ピリジン／ピラジン
KR1020157017861A KR20150092279A (ko) 2012-12-10 2013-12-06 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
CA2885392A CA2885392A1 (fr) 2012-12-10 2013-12-06 Nouvelles phenylpyridines/pyrazines a deux cycles pour le traitement du cancer
RU2015124917A RU2015124917A (ru) 2012-12-10 2013-12-06 Новые бициклические фенилпиридины/пиразины для лечения рака
CN201380064513.2A CN104837842A (zh) 2012-12-10 2013-12-06 新型二环苯基-吡啶/吡嗪用于治疗癌症
US14/735,348 US20150266878A1 (en) 2012-12-10 2015-06-10 Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
HK16101393.3A HK1213544A1 (zh) 2012-12-10 2016-02-05 新型二環苯基-吡啶/吡嗪用於治療癌症

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/086275 2012-12-10
CNPCT/CN2012/086275 2012-12-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNPCT/CN2012/086275 Continuation 2012-12-10 2012-12-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/735,348 Continuation US20150266878A1 (en) 2012-12-10 2015-06-10 Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer

Publications (1)

Publication Number Publication Date
WO2014090692A1 true WO2014090692A1 (fr) 2014-06-19

Family

ID=49713100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/075751 WO2014090692A1 (fr) 2012-12-10 2013-12-06 Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer

Country Status (10)

Country Link
US (1) US20150266878A1 (fr)
EP (1) EP2928893A1 (fr)
JP (1) JP2016501251A (fr)
KR (1) KR20150092279A (fr)
BR (1) BR112015008037A2 (fr)
CA (1) CA2885392A1 (fr)
HK (1) HK1213544A1 (fr)
MX (1) MX2015007097A (fr)
RU (1) RU2015124917A (fr)
WO (1) WO2014090692A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610229A (zh) * 2015-01-21 2015-05-13 上海皓元生物医药科技有限公司 一种是atp竞争性小分子akt抑制剂a443654的合成方法
WO2017076968A1 (fr) 2015-11-03 2017-05-11 Lu License Ab Composés destinés au traitement de désordres hyperprolifératifs
JP2017525717A (ja) * 2014-08-22 2017-09-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ インダゾール
WO2018139660A1 (fr) 2017-01-30 2018-08-02 国立大学法人京都大学 Nouveau composé, et procédé de production de lymphocytes t régulateurs
WO2019068613A1 (fr) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh Nouveaux composés de [1,6]naphthyridine et dérivés utilisés en tant qu'inhibiteurs de cdk8/cdk19
WO2021061053A1 (fr) * 2019-09-26 2021-04-01 Agency For Science, Technology And Research (A*Star) Composés thérapeutiques et leurs procédés d'utilisation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503486A (ja) 2017-11-20 2021-02-12 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物ならびに組成物および使用法
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
CN112218849B (zh) * 2018-04-06 2023-08-18 巴斯夫欧洲公司 用于制备胺的方法
AU2019419414A1 (en) * 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2021263129A1 (fr) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Composés inhibiteurs de kinase, compositions et méthodes d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases
WO2006010637A2 (fr) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
WO2007032936A2 (fr) * 2005-09-09 2007-03-22 Schering Corporation Nouveaux derives 4-cyano, 4-amino, et 4-aminomethyl des composes pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine et 2h-indazole, et nouveaux derives 5-cyano, 5-amino, et 5-aminomethyl des composes imidazo[1,2-a]pyridine, et imidazo[1,5-a]pyrazine pouvant servir d'inhibiteurs d
WO2009117156A1 (fr) * 2008-03-21 2009-09-24 Amgen Inc. Composés de pyrazolo-pyrazinones et leurs procédés d’utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058074A1 (fr) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases
WO2006010637A2 (fr) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
WO2007032936A2 (fr) * 2005-09-09 2007-03-22 Schering Corporation Nouveaux derives 4-cyano, 4-amino, et 4-aminomethyl des composes pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine et 2h-indazole, et nouveaux derives 5-cyano, 5-amino, et 5-aminomethyl des composes imidazo[1,2-a]pyridine, et imidazo[1,5-a]pyrazine pouvant servir d'inhibiteurs d
WO2009117156A1 (fr) * 2008-03-21 2009-09-24 Amgen Inc. Composés de pyrazolo-pyrazinones et leurs procédés d’utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANSEL, H. ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, pages: 196,1456 - 1457
ANSEL, HOWARD C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT, WILLIAMS & WILKINS
BASTIN R.J. ET AL., ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, 2000, pages 427 - 435
GENNARO, ALFONSO R. ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
ROWE, RAYMOND C.: "Handbook of Pharmaceutical Excipients", 2005, PHARMACEUTICAL PRESS

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525717A (ja) * 2014-08-22 2017-09-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ インダゾール
CN104610229A (zh) * 2015-01-21 2015-05-13 上海皓元生物医药科技有限公司 一种是atp竞争性小分子akt抑制剂a443654的合成方法
WO2017076968A1 (fr) 2015-11-03 2017-05-11 Lu License Ab Composés destinés au traitement de désordres hyperprolifératifs
US11471446B2 (en) 2015-11-03 2022-10-18 Lu License Ab Compounds for treatment of hypoproliferative disorders
WO2018139660A1 (fr) 2017-01-30 2018-08-02 国立大学法人京都大学 Nouveau composé, et procédé de production de lymphocytes t régulateurs
WO2019068613A1 (fr) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh Nouveaux composés de [1,6]naphthyridine et dérivés utilisés en tant qu'inhibiteurs de cdk8/cdk19
WO2021061053A1 (fr) * 2019-09-26 2021-04-01 Agency For Science, Technology And Research (A*Star) Composés thérapeutiques et leurs procédés d'utilisation

Also Published As

Publication number Publication date
RU2015124917A (ru) 2017-01-12
KR20150092279A (ko) 2015-08-12
HK1213544A1 (zh) 2016-07-08
CA2885392A1 (fr) 2014-06-19
JP2016501251A (ja) 2016-01-18
US20150266878A1 (en) 2015-09-24
BR112015008037A2 (pt) 2017-07-04
EP2928893A1 (fr) 2015-10-14
MX2015007097A (es) 2015-09-29

Similar Documents

Publication Publication Date Title
EP2928893A1 (fr) Nouvelles phénylpyridines/pyrazines à deux cycles pour le traitement du cancer
KR102216284B1 (ko) Dna-pk 억제제
WO2021087018A1 (fr) Pyridazinones utilisées en tant qu'inhibiteurs de parp7
CN108530424B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
CA3068854A1 (fr) Inhibiteurs selectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
WO2017106634A1 (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation comme modulateurs d'interactions protéine/protéine pd-1/pd-l1
EA035499B1 (ru) Новые ингибиторы глутаминазы
WO2015158310A1 (fr) Inhibiteur de tyrosine kinase et ses utilisations
BR112016008423B1 (pt) Composto, composição farmacêutica compreendendo o mesmo e seu uso
BR112014026703B1 (pt) Inibidores de dna-pk e seus usos, composição farmacêutica e seus usos, e método de sensibilização de uma célula
WO2022166974A1 (fr) Dérivé de pyridopyrimidinone, son procédé de préparation et son utilisation
KR20200115583A (ko) Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
CN112292374B (zh) 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
WO2020038460A1 (fr) Nouvel inhibiteur de dérivé de quinoléine
WO2021041976A1 (fr) Composés indolinyle inhibiteurs de perk
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
TW202204351A (zh) 具有大環結構的化合物及其用途
WO2020215998A1 (fr) Composé hétérocyclique à cinq chaînons à base de pyrimido et son utilisation en tant qu'inhibiteur d'idh2 mutant
WO2014154723A1 (fr) Nouveaux dérivés de pyrrole pour le traitement du cancer
WO2023109751A1 (fr) Dérivé de pyrimidine ou de pyridine et son utilisation médicinale
CN108341835A (zh) 用作酪氨酸激酶抑制剂的含硼化合物
US9458106B2 (en) Phenyl-pyridine/pyrazine amides for the treatment of cancer
WO2016098793A1 (fr) Dérivé thiazole ayant un groupe guanidyle cyclique
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
CN105541792B (zh) 多环类pi3k抑制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13799602

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2885392

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015008037

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2013799602

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/007097

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015546021

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20157017861

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015124917

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015008037

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150410